HLB PanageneHLB파나진

HLB Panagene is still loss-making on a trailing basis, though its share price has rebounded sharply over the past three months.

HLB Panagene, a Korean specialty biotech focused on PNA-based materials, molecular diagnostics and immunodiagnostics, reported trailing twelve-month revenue of ₩14.7B against an operating loss of ₩3.4B for the period to H1 2026. Revenue grew 14% in 2025, but losses widened, and free cash flow over the trailing period was negative at about ₩3.5B. The share price closed at ₩1,393 on 2026-10-23, up 31.8% over three months but down 18.1% over one year.

What stands out

• Trailing operating margin is -23.2% and net margin is -22.3%, with 2025 operating loss of about ₩3.4B on ₩15.0B revenue.
• Cash of about ₩20.5B exceeds borrowings of about ₩6.1B, and liabilities are 11% of equity.
• The stock trades at 0.9x book value and 4.3x sales, with no earnings-based valuation because profits are negative.
• Foreign ownership rose slightly to 1.2% from 1.0% over 60 days, while retail investors were net buyers over the last 20 days and foreign and institutional investors were net sellers.
• Recent news focused on PNA payload optimization research presented at OTS 2026, and the filings list includes an investor relations event on 2026-10-12.

What to watch

• The next full-year or quarterly results, to see whether revenue growth can narrow the operating loss.
• Further insider and 5%+ holding filings, which have been frequent in 2026.
• Whether the share price holds after a large gain from its 52-week low of ₩980, given the stock is still well below its 52-week high of ₩2,940.